SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 1, 2024
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
000-19125
|
|
33-0336973
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
|
Common Stock, $.001 Par Value
|
|
“IONS” |
|
The Nasdaq Stock Market, LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
| Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On August 1, 2024, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s
financial results for the quarter ended June 30, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company
also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash
compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release
is furnished with this report as an exhibit pursuant to “Item 2.02. Results of Operations and Financial Condition” of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, regardless of any general incorporation language in such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press Release dated August 1, 2024.
|
| |
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Ionis Pharmaceuticals, Inc.
|
|
|
|
Dated: August 1, 2024
|
By:
|
/s/ Patrick R. O’Neil
|
|
|
Patrick R. O’Neil
|
|
|
Executive Vice President, Chief Legal Officer and General Counsel
|
Exhibit 99.1
Ionis reports second quarter 2024 financial results
WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year
Olezarsen PDUFA December 19, 2024 for FCS
Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions
On track to achieve 2024 financial guidance
CARLSBAD, Calif., August 1, 2024 – Ionis
Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the second quarter of 2024.
“Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious diseases. The WAINUA launch for
hereditary ATTR polyneuropathy (ATTRv-PN) continues to progress well with AstraZeneca. QALSODY is now approved in the EU, expanding the number of patients who can benefit from the first approved
treatment for a genetic form of ALS. And we are well positioned for our first independent launch with olezarsen, which was accepted for Priority Review with a December FDA action date for people with familial chylomicronemia syndrome (FCS), a serious and rare disease with no approved treatments in the U.S. Additionally, we completed enrollment in our Phase 3 olezarsen program for the much larger severe hypertriglyceridemia (sHTG) patient population, keeping us on track for data in the second half of next year. And based on recent positive Phase 3 results, we believe donidalorsen, our second planned
independent U.S. launch, is positioned to be a preferred choice for people with hereditary angioedema (HAE),” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “We also advanced our
next wave of potentially transformational medicines, including announcing plans to independently advance ION582 into a Phase 3 study next year, based on positive data in Angelman syndrome; this program is poised to become the cornerstone of our
robust wholly owned neurology pipeline. Our recent achievements, together with multiple upcoming catalysts, position Ionis to deliver next-level value for all stakeholders.”
Second Quarter 2024 Summary Financial Results(1):
| |
|
Three months ended
June 30,
|
|
|
Six months ended
June 30,
|
|
| |
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
| |
|
(amounts in millions)
|
|
|
Total revenue
|
|
$
|
225
|
|
|
$
|
188
|
|
|
$
|
345
|
|
|
$
|
319
|
|
|
Operating expenses
|
|
$
|
291
|
|
|
$
|
279
|
|
|
$
|
560
|
|
|
$
|
523
|
|
|
Operating expenses on a non-GAAP basis
|
|
$
|
260
|
|
|
$
|
252
|
|
|
$
|
498
|
|
|
$
|
469
|
|
|
Loss from operations
|
|
$
|
(66
|
)
|
|
$
|
(91
|
)
|
|
$
|
(215
|
)
|
|
$
|
(204
|
)
|
|
Loss from operations on a non-GAAP basis
|
|
$
|
(35
|
)
|
|
$
|
(64
|
)
|
|
$
|
(153
|
)
|
|
$
|
(150
|
)
|
| |
(1) |
Reconciliation of GAAP to non-GAAP basis contained later in this release.
|
Financial Highlights
| • |
Revenue increased for the second quarter and first half of 2024 by 20% and 8% compared to the same periods last year, respectively, primarily driven by an increase in R&D revenue reflecting the
value Ionis’ pipeline and technology continues to generate
|
| • |
Operating expenses increased in the second quarter and first half of 2024 compared to the same periods last year, reflecting continued strategic investments in late-stage development, including
WAINUA for ATTR cardiomyopathy and olezarsen for sHTG, and commercialization efforts for WAINUA, olezarsen and donidalorsen
|
| • |
Reaffirmed 2024 financial guidance
|
Recent Marketed Medicines Highlights
| • |
WAINUA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) generated sales of $16 million and $21 million resulting in royalty revenue of $4
million and $5 million in the second quarter and first half of 2024, respectively
|
| • |
WAINUA for the treatment of adults with ATTRv-PN approved in Canada
|
| • |
SPINRAZA for the treatment of spinal muscular atrophy (SMA) generated global sales of $429 million and $770 million resulting in royalty revenue of $57 million and $95 million in the second quarter
and first half of 2024, respectively
|
| • |
QALSODY for the treatment of SOD1-ALS granted marketing approval in the EU
|
Recent Late-Stage Pipeline Highlights
| • |
Olezarsen achieved multiple clinical and regulatory milestones that support pursuit of two patient populations with urgent unmet need, familial chylomicronemia syndrome (FCS) and severe
hypertriglyceridemia (sHTG):
|
|
o |
FDA accepted the NDA for patients with FCS for Priority Review with a PDUFA date of December 19, 2024
|
|
o |
Presented positive Phase 3 Balance study data in patients with FCS with a simultaneous publication in the New England Journal of
Medicine
|
|
o |
Opened Expanded Access Program (EAP) for FCS in the U.S.
|
|
o |
Completed enrollment for all Phase 3 sHTG studies: CORE pivotal study, CORE2 confirmatory pivotal study and ESSENCE supportive exposure study; on track for data across all three studies in H2:2025
|
|
o |
Presented positive Phase 2b Bridge study data in patients with HTG and sHTG with a simultaneous publication in the New England
Journal of Medicine
|
| • |
Donidalorsen achieved multiple clinical milestones positioning it to become the first RNA-targeted prophylactic treatment for people with hereditary angioedema (HAE):
|
|
o |
Preparing to submit NDA
|
|
o |
Otsuka preparing to submit MAA; expanded Otsuka EU commercial licensing agreement to include Asia Pacific
|
|
o |
Presented positive Phase 3 OASIS-HAE study data in patients treated every four weeks or every eight weeks with a simultaneous publication in the New England Journal of Medicine
|
|
o |
Presented positive Phase 3 OASISplus open-label extension study data in patients treated every four weeks or every eight weeks
|
|
o |
Presented positive Phase 3 OASISplus switch study data in patients previously treated with other prophylactic therapies
|
| • |
Zilganersen (GFAP) Phase 3 study for the treatment of patients with Alexander disease fully enrolled; on track for data in 2025
|
| • |
Bepirovirsen Phase 3 studies for the treatment of patients with chronic hepatitis B (CHB) fully enrolled; on track for data in 2026
|
Recent Other Pipeline Updates
| • |
Presented positive Phase 2 data for ION582 (UBE3A), our wholly owned medicine, in patients with Angelman syndrome; preparing for meetings with global regulators ahead of planned Phase 3 study start
in H1:2025
|
| • |
Presented positive Phase 2 data for ION224 (DGAT2) in patients with metabolic dysfunction-associated steatohepatitis (MASH)
|
| • |
Initiated the Phase 1/2 Orbit study of ION356 (PLP1) in patients with Pelizaeus-Merzbacher disease (PMD)
|
| • |
Discontinued development of IONIS-FB-LRx for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) following completion of Phase 2 studies showing favorable safety
profiles and good target engagement, but insufficient efficacy to advance into Phase 3 development
|
Second Quarter 2024 Financial Results
“Ionis is at a critical inflection point. We have achieved important development and regulatory milestones for WAINUA, olezarsen and donidalorsen, all of which have
significant potential to help patients in need. In parallel, we continue to advance our next wave of potentially transformational medicines,” said Elizabeth L. Hougen, chief financial officer of Ionis. “To drive next-level of value creation for all
stakeholders, we remain focused on strategically investing our capital to fully unlock the potential of our promising near-and longer-term portfolio. Our investments are focused on go-to-market preparations for our upcoming planned olezarsen and
donidalorsen launches. And with our increased confidence in the potential of WAINUA and olezarsen to address broader patient populations, we are planning additional investments to scale our capabilities in line with the significant potential that
these important medicines represent. Additionally, we are investing in our next wave of medicines, including pre-commercialization activities and Phase 3 development for ION582 for Angelman syndrome, which we plan to start in the first half of next
year. We expect our investments today and in the years ahead will position Ionis for sustainable growth for years to come.”
Revenue
Ionis’ revenue was comprised of the following:
| |
|
Three months ended
|
|
|
Six months ended
|
|
| |
|
June 30,
|
|
|
June 30,
|
|
| |
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
|
Revenue:
|
|
(amounts in millions)
|
|
|
Commercial revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPINRAZA royalties
|
|
$
|
57
|
|
|
$
|
61
|
|
|
$
|
95
|
|
|
$
|
111
|
|
|
WAINUA royalties
|
|
|
4
|
|
|
|
-
|
|
|
|
5
|
|
|
|
-
|
|
|
Other commercial revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TEGSEDI and WAYLIVRA revenue, net
|
|
|
8
|
|
|
|
11
|
|
|
|
17
|
|
|
|
17
|
|
|
Licensing and other royalty revenue
|
|
|
3
|
|
|
|
6
|
|
|
|
15
|
|
|
|
18
|
|
|
Total commercial revenue
|
|
|
72
|
|
|
|
78
|
|
|
|
132
|
|
|
|
146
|
|
|
Research and development revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization from upfront payments
|
|
|
35
|
|
|
|
15
|
|
|
|
77
|
|
|
|
29
|
|
|
Milestone payments
|
|
|
53
|
|
|
|
51
|
|
|
|
60
|
|
|
|
74
|
|
|
License fees
|
|
|
38
|
|
|
|
20
|
|
|
|
38
|
|
|
|
20
|
|
|
Other services
|
|
|
15
|
|
|
|
4
|
|
|
|
16
|
|
|
|
6
|
|
|
Collaborative agreement revenue
|
|
|
141
|
|
|
|
90
|
|
|
|
191
|
|
|
|
129
|
|
|
WAINUA joint development revenue
|
|
|
12
|
|
|
|
20
|
|
|
|
22
|
|
|
|
44
|
|
|
Total research and development revenue
|
|
|
153
|
|
|
|
110
|
|
|
|
213
|
|
|
|
173
|
|
|
Total revenue
|
|
$
|
225
|
|
|
$
|
188
|
|
|
$
|
345
|
|
|
$
|
319
|
|
Commercial revenue in the second quarter and first half of 2024 included a new source of royalty revenue with the launch of WAINUA in the U.S. in late January 2024.
Ionis’ commercial revenue in the second quarter and first half of 2024 also included royalties from the net sales of QALSODY, which Biogen launched in the U.S. in the second quarter of 2023 and in the EU in the second quarter of 2024.
R&D revenue in the second quarter and first half of 2024 increased compared to the same periods last year primarily due to the amortization of upfront payments from
the new collaborations with Roche and Novartis that Ionis entered into during the second half of last year. In addition, license fees increased year over year as a result of new collaborations
Ionis entered into during the second quarter of 2024, including the expanded donidalorsen licensing agreement with Otsuka, which now includes the Asia-Pacific region in addition to Europe. These increases were partially offset by the decrease in
WAINUA joint development revenue, which decreased as development activities relating to ATTRv-PN wound down with the launch of WAINUA for this indication.
Operating Expenses
Ionis’ operating expenses increased in the second quarter and first half of 2024 compared to the same periods in 2023, consistent with expectations. SG&A expenses
increased year over year primarily due to the launch of WAINUA in the U.S. and launch preparation activities for olezarsen and donidalorsen, including establishing the field team for olezarsen. R&D expenses decreased in the second quarter and
were essentially flat in the first half of 2024 compared to the same periods last year as several late-stage studies have ended.
Balance Sheet
As of June 30, 2024, Ionis’ cash, cash equivalents and short-term investments decreased to $2.1 billion compared to $2.3 billion at December 31, 2023. The Company plans
to continue deploying its capital resources toward growth opportunities, and as previously guided, projects to end 2024 with $1.7 billion in cash, cash equivalents and short-term investments.
Ionis’ working capital also decreased over the same period primarily due to the Company’s lower cash and short-term investments balance. We expect to make increased strategic investments in the years ahead, with a focus on late-stage programs, wholly
owned assets, and our next wave of innovative medicines.
Webcast
Management will host a conference call and webcast to discuss Ionis’ second quarter 2024 results at 11:30 a.m. Eastern time on Thursday, August 1, 2024.
Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company’s second quarter 2024 earnings slides click
here.
For more information about SPINRAZA and QALSODY, visit https://www.spinraza.com/ and https://www.qalsody.com/, respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY.
Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).
INDICATION for WAINUA™ (eplontersen)
WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in
adults.
IMPORTANT SAFETY INFORMATION for WAINUA™ (eplontersen)
WARNINGS AND PRECAUTIONS
Reduced Serum Vitamin A Levels and Recommended Supplementation WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.
ADVERSE REACTIONS
Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).
Please see link to U.S. Full Prescribing Information for WAINUA.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines
and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep
understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com
and follow us on X (Twitter) and LinkedIn.
Ionis’ Forward-looking Statement
This press release includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of our commercial
medicines, additional medicines in development and technologies. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.
Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building
a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking
statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update
any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K
for the year ended December 31, 2023, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea
Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA® and QALSODY® are registered trademarks of Biogen. WAINUATM is a registered trademark of the AstraZeneca group of companies.
Ionis Investor Contact:
D. Wade Walke, Ph.D.
IR@ionis.com
760-603-2331
Ionis Media Contact:
Hayley Soffer
media@ionis.com
760-603-4679
IONIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Millions, Except Per Share Data)
| |
|
Three months ended
|
|
|
Six months ended
|
|
| |
|
June 30,
|
|
|
June 30,
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
| |
|
(unaudited)
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPINRAZA royalties
|
|
$
|
57
|
|
|
$
|
61
|
|
|
$
|
95
|
|
|
$
|
111
|
|
|
WAINUA royalties
|
|
|
4
|
|
|
|
-
|
|
|
|
5
|
|
|
|
-
|
|
|
Other commercial revenue
|
|
|
11
|
|
|
|
17
|
|
|
|
32
|
|
|
|
35
|
|
|
Total commercial revenue
|
|
|
72
|
|
|
|
78
|
|
|
|
132
|
|
|
|
146
|
|
|
Research and development revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative agreement revenue
|
|
|
141
|
|
|
|
90
|
|
|
|
191
|
|
|
|
129
|
|
|
WAINUA joint development revenue
|
|
|
12
|
|
|
|
20
|
|
|
|
22
|
|
|
|
44
|
|
|
Total research and development revenue
|
|
|
153
|
|
|
|
110
|
|
|
|
213
|
|
|
|
173
|
|
|
Total revenue
|
|
|
225
|
|
|
|
188
|
|
|
|
345
|
|
|
|
319
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
4
|
|
|
|
3
|
|
|
|
6
|
|
|
|
4
|
|
|
Research, development and patent
|
|
|
222
|
|
|
|
230
|
|
|
|
436
|
|
|
|
428
|
|
|
Selling, general and administrative
|
|
|
65
|
|
|
|
46
|
|
|
|
118
|
|
|
|
91
|
|
|
Total operating expenses
|
|
|
291
|
|
|
|
279
|
|
|
|
560
|
|
|
|
523
|
|
|
Loss from operations
|
|
|
(66
|
)
|
|
|
(91
|
)
|
|
|
(215
|
)
|
|
|
(204
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense related to the sale of future royalties
|
|
|
(18
|
)
|
|
|
(18
|
)
|
|
|
(36
|
)
|
|
|
(33
|
)
|
|
Other income, net
|
|
|
18
|
|
|
|
32
|
|
|
|
42
|
|
|
|
47
|
|
|
Loss before income tax expense
|
|
|
(66
|
)
|
|
|
(77
|
)
|
|
|
(209
|
)
|
|
|
(190
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
-
|
|
|
|
(8
|
)
|
|
|
-
|
|
|
|
(20
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(66
|
)
|
|
$
|
(85
|
)
|
|
$
|
(209
|
)
|
|
$
|
(210
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(0.45
|
)
|
|
$
|
(0.60
|
)
|
|
$
|
(1.43
|
)
|
|
$
|
(1.47
|
)
|
|
Shares used in computing basic and diluted net loss per share
|
|
|
146
|
|
|
|
143
|
|
|
|
146
|
|
|
|
143
|
|
IONIS PHARMACEUTICALS, INC.
Reconciliation of GAAP to Non-GAAP Basis:
Condensed Consolidated Operating Expenses, Loss From Operations, and Net Loss
(In Millions)
| |
|
Three months ended
June 30,
|
|
|
Six months ended
June 30,
|
|
| |
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
| |
|
(unaudited)
|
|
|
As reported research, development and patent expenses according to GAAP
|
|
$
|
222
|
|
|
$
|
230
|
|
|
$
|
436
|
|
|
$
|
428
|
|
|
Excluding compensation expense related to equity awards
|
|
|
(23
|
)
|
|
|
(19
|
)
|
|
|
(45
|
)
|
|
|
(39
|
)
|
|
Non-GAAP research, development and patent expenses
|
|
$
|
199
|
|
|
$
|
211
|
|
|
$
|
391
|
|
|
$
|
389
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As reported selling, general and administrative expenses according to GAAP
|
|
$
|
65
|
|
|
$
|
46
|
|
|
$
|
118
|
|
|
$
|
91
|
|
|
Excluding compensation expense related to equity awards
|
|
|
(8
|
)
|
|
|
(7
|
)
|
|
|
(17
|
)
|
|
|
(14
|
)
|
|
Non-GAAP selling, general and administrative expenses
|
|
$
|
57
|
|
|
$
|
39
|
|
|
$
|
101
|
|
|
$
|
77
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As reported operating expenses according to GAAP
|
|
$
|
291
|
|
|
$
|
279
|
|
|
$
|
560
|
|
|
$
|
523
|
|
|
Excluding compensation expense related to equity awards
|
|
|
(31
|
)
|
|
|
(27
|
)
|
|
|
(62
|
)
|
|
|
(54
|
)
|
|
Non-GAAP operating expenses
|
|
$
|
260
|
|
|
$
|
252
|
|
|
$
|
498
|
|
|
$
|
469
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As reported loss from operations according to GAAP
|
|
$
|
(66
|
)
|
|
$
|
(91
|
)
|
|
$
|
(215
|
)
|
|
$
|
(204
|
)
|
|
Excluding compensation expense related to equity awards
|
|
|
(31
|
)
|
|
|
(27
|
)
|
|
|
(62
|
)
|
|
|
(54
|
)
|
|
Non-GAAP loss from operations
|
|
$
|
(35
|
)
|
|
$
|
(64
|
)
|
|
$
|
(153
|
)
|
|
$
|
(150
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As reported net loss according to GAAP
|
|
$
|
(66
|
)
|
|
$
|
(85
|
)
|
|
$
|
(209
|
)
|
|
$
|
(210
|
)
|
|
Excluding compensation expense related to equity awards and related tax effects
|
|
|
(31
|
)
|
|
|
(27
|
)
|
|
|
(62
|
)
|
|
|
(54
|
)
|
|
Non-GAAP net loss
|
|
$
|
(35
|
)
|
|
$
|
(58
|
)
|
|
$
|
(147
|
)
|
|
$
|
(156
|
)
|
Reconciliation of GAAP to Non-GAAP Basis
As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP loss from operations, and non-GAAP net loss were
adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. These measures are provided as supplementary information and are not a substitute for
financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further,
the presentation of Ionis’ non-GAAP results is consistent with how Ionis’ management internally evaluates the performance of its operations.
IONIS PHARMACEUTICALS, INC.
Condensed Consolidated Balance Sheets
(In Millions)
| |
|
June 30,
2024
|
|
|
December 31,
2023
|
|
| |
|
(unaudited)
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
Cash, cash equivalents and short-term investments
|
|
$
|
2,079
|
|
|
$
|
2,331
|
|
|
Contracts receivable
|
|
|
27
|
|
|
|
98
|
|
|
Other current assets
|
|
|
223
|
|
|
|
213
|
|
|
Property, plant and equipment, net
|
|
|
76
|
|
|
|
71
|
|
|
Right-of-use assets
|
|
|
167
|
|
|
|
172
|
|
|
Other assets
|
|
|
119
|
|
|
|
105
|
|
|
Total assets
|
|
$
|
2,691
|
|
|
$
|
2,990
|
|
| |
|
|
|
|
|
|
|
|
|
Liabilities and stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
Current portion of deferred contract revenue
|
|
$
|
94
|
|
|
$
|
151
|
|
|
0.125% convertible senior notes, net – short-term
|
|
|
44
|
|
|
|
44
|
|
|
Other current liabilities
|
|
|
168
|
|
|
|
253
|
|
|
1.75% convertible senior notes, net
|
|
|
564
|
|
|
|
562
|
|
|
0% convertible senior notes, net
|
|
|
627
|
|
|
|
625
|
|
|
Liability related to sale of future royalties, net
|
|
|
534
|
|
|
|
514
|
|
|
Long-term lease liabilities
|
|
|
166
|
|
|
|
171
|
|
|
Long-term obligations, less current portion
|
|
|
41
|
|
|
|
42
|
|
|
Long-term deferred contract revenue
|
|
|
189
|
|
|
|
241
|
|
|
Total stockholders’ equity
|
|
|
264
|
|
|
|
387
|
|
|
Total liabilities and stockholders’ equity
|
|
$
|
2,691
|
|
|
$
|
2,990
|
|
Key 2024 Value Driving Events(1)
| |
New Product Launches
|
| |
Program
|
|
Indication
|
Achieved
|
| |
WAINUA
|
|
ATTRv-PN
|
|
| |
Olezarsen
|
|
FCS
|
|
| |
QALSODY (EU)
|
|
SOD1-ALS
|
|
| |
Regulatory Actions
|
| |
Program
|
|
Indication
|
|
Regulatory Action
|
Achieved
|
| |
Eplontersen
|
|
ATTRv-PN
|
|
Additional OUS filings
|
|
|
|
EMA approval decision
|
|
|
|
Additional OUS approval decision(s)
|
|
| |
Olezarsen
|
|
FCS
|
|
NDA filing
|
|
|
|
FDA approval decision
|
|
|
EU filing
|
|
|
|
Canada filing
|
|
| |
Donidalorsen
|
|
HAE
|
|
NDA filing
|
|
| |
QALSODY
|
|
SOD1-ALS
|
|
EMA approval decision
|
|
| |
Key Phase 3 Clinical Data Events
|
| |
Program
|
|
Indication
|
|
Event
|
Achieved
|
| |
Olezarsen
|
|
FCS
|
|
Balance study full data
|
|
| |
Donidalorsen
|
|
HAE
|
|
OASIS-HAE topline data
|
|
| |
Donidalorsen
|
|
HAE
|
|
OASIS-HAE full data
|
|
| |
Donidalorsen
|
|
HAE
|
|
OASIS-Plus: OLE + Switch data
|
|
| |
SPINRAZA
|
|
SMA
|
|
DEVOTE study data (high dose)
|
|
| |
Key Phase 2 Clinical Data Events
|
| |
Program
|
|
Indication
|
|
Event
|
Achieved
|
| |
Donidalorsen
|
|
HAE
|
|
3-year Phase 2 OLE data
|
|
| |
IONIS-FB-LRx
|
|
IgAN
|
|
Phase 2 data
|
|
| |
IONIS-FB-LRx
|
|
GA
|
|
GOLDEN study data
|
-
|
| |
ION224 (DGAT2)
|
|
NASH
|
|
Phase 2 data
|
|
| |
ION582 (UBE3A)
|
|
Angelman syndrome
|
|
HALOS study data
|
|
| |
ION541 (ATXN2)
|
|
ALS
|
|
ALSpire study data
|
-
|
| |
(1) |
Timing expectations based on current assumptions and subject to change.
|
# # #
9